Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 21

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

384

HTML

3527

Figures (1-1)

199

Tables (1-2)

185

Sum=4295

Jun 7, 2006 (publication date) through Sep 1, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Jun 7, 2006; 12(21): 3297-3305
Published online Jun 7, 2006. doi: 10.3748/wjg.v12.i21.3297

Table 2 Therapeutics targeting the EGFR family

Agent	Type	Target	Status
Trastuzumab	Humanized mAb	erbB2	Approved for breast cancer
Pertuzumab	Humanized mAb	erbB2	Phase II trials
Cetuximab	Chimeric mAb	EGFR	Approved for colorectal cancer
Matuzumab	Humanized mAb	EGFR	Phase II trials
Panitumab	Humanized mAb	EGFR	Trials ongoing
Gefitinib	TKI	EGFR	Approved for NSCLC
Erlotinib	TKI	EGFR	Approved for NSCLC
Lapatinib	TKI	EGFR/erbB2	Phase III trial / breast cancer
AEE788	TKI	EGFR/ erbB2/ VEGFR	Phase I trials
CI-1033	Irreversible TKI	EGFR/erbB2	Phase II trials
EKB-569	Irreversible TKI	EGFR/erbB2	Phase II trials
EXEL 7647 / EXEL 0999	TKI	EGFR/ erbB2/ VEGFR	Phase I trials

(incomplete list; modified according to ref. 44)

Citation: Becker J, Müller-Tidow C, Serve H, Domschke W, Pohle T. Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy. World J Gastroenterol 2006; 12(21): 3297-3305
URL: https://www.wjgnet.com/1007-9327/full/v12/i21/3297.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i21.3297